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The interaction between nutrition and infection is a key determinant of human health. Traditionally the interaction has centered on the role of
nutrients in defining host defenses and the impact of infection in defining nutritional needs and status. Over the past decades the interaction
has expanded its scope to encompass the role of specific nutrients in defining acquired immune function, in the modulation of inflammatory pro-
cesses and on the virulence of the infectious agent itself. More recently the role of micronutrients and fatty acids on the response of cells and
tissues to hypoxic and toxic damage has been recognized suggesting a fourth dimension to the interaction. The list of nutrients affecting infection,
immunity, inflammation and cell injury has expanded from traditional protein-energy supply to several vitamins, multiple minerals and more
recently specific lipid components of the diet. The promise of nutrition in the defense against infection, inflammation and tissue injury has spawned
a thriving pharma-nutritional supplement industry and the development of novel foods that require appropriate evaluation of efficacy, safety and
effectiveness relative to costs. Academics need to aware of the ethics and the pitfalls in the interaction with industry; conversely industry has to
define its role in the process of bringing new knowledge to useful products. The process needs to be interactive, transparent and clearly place
public interest above all other considerations.
Traditionally, the study of the interaction between nutrition
and infection (as “the first I”) has encompassed the role of
infection in defining nutritional status and the role of nutrition
in determining host defence mechanisms. This concept
emerged from multiple observations in developing countries
(India, Africa and Central America) was captured in a classic
monograph by Scrimshaw, Taylor and Gordon1. Young chil-
dren became infected, ate less and lost more nutrients than
normal, and stopped growing. Thus the relationship between
the diet and nutritional status was considered as a triangle
where the interaction of diet and infection defined nutritional
status. The realisation that case fatality from infections more
than incidence was affected by nutritional deficits lead to
research on the role of nutrition on specific components of
host defence systems. The epidemiologic and laboratory
work of Mata in Central America2, Chandra in India3, and
Suskind in Thailand4, amongst other research workers
served to firmly establish the critical role of protein energy
malnutrition in defining not only cellular and humoral
immune function but also non-specific host defence systems.
Further methodological advances facilitated the study of cellu-
lar and molecular mechanisms underlying the initial clinical
observations derived mainly from malnourished infants in
poor countries5. These observations were soon followed by
studies of malnourished hospitalised adult patients in industri-
alised countries demonstrating that the effects were of great
significance to both adults and children, and had a major
impact on global health6. The progressive understanding that
protein-energy malnutrition (PEM) was not only protein and
energy deficiency but also involved insufficiencies in the cel-
lular supply of multiple micronutrients, served to highlight the
importance of specific micronutrients (vit A, Fe, Zn and
Copper) and their respective carrier proteins (retinol binding
protein [RBP], transferrin, albumin and ceruloplasmin) on
specific and non-specific components of the immune
response7,8. This knowledge led to the need to include immu-
nity as the link in the relationship between nutrition and infec-
tion (“the second I”). The scientific impetus generated by the
emergence of knowledge about the immune system and the
associated myriad of effects and interactions, mediated by
local tissue and circulating hormones, set the stage for a
new layer of complexity for nutritional effects on infection,
beyond the traditional immune response, to reveal itself 9.
The linkage chain now included nutrition, infection, immunity
and the inflammatory response. The role of classical nutrients
in defining inflammation was a bit harder to establish; since
cytokines, genetically coded, potent circulating peptides that
act in minuscule amounts, left little room for a convincing
effect of diet on the inflammatory response. In fact, traditional
essential nutrients such as tocopherol, retinol and zinc do not
modify cytokines in their actual aminoacid composition or
serve as building blocks to form them, but act to regulate
the process, modulating the intensity of the responses that
define the inflammatory process. Parallel advances in lipid
biochemistry, with major implications for nutrition, contribu-
ted to the resolution of this issue. The fact that essential
fatty acids and the product of their metabolism (arachidonic,
eicosapentaenoic and docosahexaenoic acids) were both key
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components of cell membranes and at the same time served as
precursors for mediators of the inflammatory and the immune
response served to spark renewed interest on the potential
influence of nutrition on inflammatory processes. This time
the effects of nutrients were centre stage in the inflammatory
phenomena; nutritional epidemiology considering comparative
studies of the high n-3 fatty acid Eskimo diet vs. the high n-6
fatty acid western diets served to highlight the importance
of the balance of these mediators and the contrast of the
effects illustrated the potential health gains from modulating
the quality of the lipid intake10,11. This knowledge paved
the way for the inclusion of inflammation as “the third I” in
the relationship between nutrition and infection. We have
only begun to elucidate how lipid moieties and micronutrients
interact, both in their genuine nutritional role and also as
part of the oxidant/antioxidant system that is both causally
and consequentially related to infection, immunity and inflam-
mation. The role of tocopherols as key antioxidants in
promoting normal host defences but also in compromising
phagocytes and the bacterial killing capacity of leukocytes
when in excess serve to underpin the scientific basis of
the epidemiologic observations. The demonstration of an
open U shaped risk versus dose response can now be
explained, too little vitamin E compromises the immune
system while excess tocopherol interferes with superoxide
production, leading to increased mortality12,13. Some may
even suggest the need for a “fourth I” considering that
nutrients also modulate injury as an end point of hypoxic or
toxin mediated cell damage. The newly discovered resolvins
derived from essential lipids are opening the way for
new thinking on how dietary components can prevent
further injury after infections, microbial toxins and hypoxia.
In fact, the demonstration that 10,17S-docosatriene is able to
reduce post hypoxic brain infarcts and release of re-perfusion
injury mediators, offers new hope into ailments that up to
now have proven fairly resistant to preventive or curative
actions. In addition, knowledge of how docosahexaenoic
acid DHA and related compounds are able to block the
effect of platelet activating factor PAF and other cytokine
tissue injury mediators, limiting inflammation and injury
after endotoxin-lipopolysaccharide induced injury, creates
new opportunities to modulate these phenomena under
health and disease conditions14,15.
Academia-Industry Partnerships: learning from past and
recent experience
How do potential academic-industry partnerships (AIPs) fit
into the picture of Infection-Immunity-Inflammation inter-
actions? Based on the brief review presented in the preceding
section it is clear that there are multiple business opportu-
nities related to food products or specific food components
that may affect the range of potential interactions described.
Given the limitations of space, I will not discuss in this paper
the potential health effects of essential and non essential
nutrients in foods. In fact the agenda and scientific pro-
gramme of the meeting, the industry sponsorship and the
exhibitions provide a clear indication of the health signifi-
cance of the science generated in the field on nutrition-infec-
tion-inflammation-injury. The application of this science to
the design of products and to the appropriate evaluation of
the potential risks and benefits derived from their use is
clearly an area of interface between scientists, industry and
regulators. The purpose of this paper is to address selective
issues that should be taken into account in advancing partner-
ships that are of interest to the public in terms of their health
and well being while preserving the essence of the science
we conduct in concordance with the public trust placed in
us as scientists.
Evaluation of health effects of foods and food components
Foods used for special medical purposes are traditionally pre-
scribed by physicians to meet specific nutritional requirements
in patients who are malnourished due to disease and/or poor
diet. These products are used under medical supervision, and
their indications for use are based on sound clinical evidence
of efficacy and safety. A wide array of such products exists,
and their indications typically have evolved as research into
their beneficial effects is conducted16,17.
Functional foods and novel ingredients are food products
used to promote optimal health. The composition of these
products is not necessarily regulated, making for a broad
compositional diversity among products. The term ‘functional
foods’ has been defined to mean foods which demonstrate a
beneficial effect beyond the obvious nutritional effects in
terms of provision of both essential and non essential nutri-
ents17. These effects might include an improved state of
health and well-being or a reduction in the risks associated
with certain diseases. Novel ingredients are also being eval-
uated for potential use as therapeutic agents. Pre- and Pro-
biotics are examples of novel ingredients that can modulate
the intestinal microflora; phytoestrogens and carotenoids are
other examples of novel ingredients with potential health
benefits for bone health and cancer risk. Food components
that affect lipid and carbohydrate metabolism, and defence
against oxidative damage are also of interest. There is cer-
tainly a place in medical and public health practice for func-
tional foods that have been tested rigorously and are proven
safe and beneficial in promoting health and well being, or in
preventing functional losses. Some of the important targets
for their use include child growth and development, bone
health and immune function especially during early life and
in ageing. Because the concept of functional foods and
novel ingredients is relatively new, regulatory frameworks
or guidelines to assess efficacy and effectiveness are often
poorly defined or in some cases not available. While there
is some agreement that functional food products and novel
ingredients should be evaluated for efficacy and safety by
formulating and testing specific hypotheses, few guidelines
are currently in place except for those where health claims
are being considered. If many of the products in the market
were examined, few would have solid and sufficient
evidence of effectiveness in terms of disease prevention
under real world conditions although most would meet
safety standards17.
Industry and academia are increasingly coming together to
create products which will meet specific consumer demands
or perceived needs. An admittedly oversimplified view of
the relationship between academia, industry, and consumers
is that academia is driven by science, industry by profit, and
consumers are driven by the benefits they derive from the
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products produced by industry. It is important to look at how
successful partnerships between academia and industry are
formed, and what are the responsibilities of each partner in
taking products from scientific innovation to product develop-
ment and to their final place in the food supply. Typically,
academia and industry first come together to develop a
scientific concept in response to a consumer need, whether
established or perceived. The scientific basis for innovation
serves to focus product development as well as to determine
what consumer education efforts will be necessary to ensure
that the product will then be accepted and in demand. Consu-
mers often have insufficient knowledge of the many factors
that determine their nutrition, health and well being. They
may not know much about the role of the specific nutrients
included in a product until they learn of the potential benefits
of that product. Academic-Industry Partnerships can play
an important role in disseminating and supporting consumer
education. Consumers are commonly rightfully skeptical of
information coming from a source that stands to make a
profit, be it from the private or the academic sector. This
reinforces the role for academia in providing independent
scientific advice and education to consumers. It is worth reiter-
ating that no matter how successful the marketing and consu-
mer education efforts are by themselves, unless the innovation
has a strong scientific base, sooner or later it will fail.
Once the concept has a well established scientific base, the
potential products can be considered. However before actually
formulating a product for testing, the safety of the potential
product must be thoroughly considered. This is a necessary
but insufficient step, since in the final analysis any purchase
involves a cost benefit assessment from the viewpoint of the
consumer. The fact is that unless consumers perceive
that the gain they will obtain from consuming the product is
greater that the monetary outlay they make, they will not
buy it. These assessments are necessary before taking the
product concept any further. Academia can play a major
role in evaluating safety risks and perceived or real benefits
to consumers. Here is where sound research methods and
well validated results are essential. The academic and indus-
trial partners should develop a database to support not only
the efficacy and safety of all products under development,
but also the effectiveness which can only be measured
under real life conditions. The evaluation should be continued
after the product is placed in the market. As part of the
risk benefit analysis, industry must estimate costs and
profits to determine if the product concept is economically
viable and if it will yield a profit. Investors will explore
alternative options if, on final analysis, the product is not
sufficiently profitable or if the opportunity costs are exces-
sively high16.
Post-marketing surveillance of food products is associated
with both opportunities and challenges. Data obtained after
product launch is complementary to the kinds of data that
can be obtained from pre-market clinical trials. For instance,
a higher number of people will be exposed to the product for
a longer duration in post-marketing studies, thus the impact
can be assessed beyond biomarkers of disease and measured
by prevention of more relevant endpoints. This need not con-
sider only clinically relevant effects but also prevention of
disability [loss of disability adjusted life years (DALYs)] or
quality of life indicators [quality adjusted life years
(QUALYs)]. Interactions with other dietary or lifestyle fac-
tors that may have been difficult to evaluate in the pre-
market trials may surface in the post marketing studies.
The actual use of products often differs from their intended
use, providing an opportunity to look at product consumption
in a more realistic way. The observation of actual product
consumption allows identification of potential risks and
evaluation of potential benefits in specific sub groups that
were not identified prior to the introduction to the market.
Post-marketing surveillance studies, although typically
designed to monitor adverse reactions of drugs, can also pro-
vide an opportunity to study product effectiveness, and assess
the changes in dietary patterns and nutritional status that can
be related to the entry of a product to the market. There are
two main types of post-marketing studies; passive or active
surveillance studies. One example of passive surveillance
would be a toll free telephone number for consumers to
call and provide their opinions on a product as well as
record any adverse reactions they had experienced. The uti-
lity of these studies for food products is limited, because
the studies rely on voluntary reports from consumers and
health professionals. The characteristics of individuals who
take the time to call in may be very different from those
who do not; in addition, it is very difficult to establish a
true causal link from passive surveillance. These studies
thus serve mainly to alert for potential problems; nevertheless
they are important to monitor since it serves to identify the
impact of concurrent events that affect consumers, such as
media reports or adverse publicity that can induce surges in
feedback which can then be put into perspective. Active sur-
veillance involves either observational or experimental
studies. While there is a great deal of expertise in conducting
active nutritional studies that examine the relationship
between food intake and health effects, the experience is pri-
marily with generic foods and not with branded products.
Evaluating individual consumption data and population con-
sumption data is quite different; each requires a distinct
methodology to measure the outcome parameter. Lack of
data on novel food ingredients, presumably due to lack of
information on use, complicates these evaluations. A nar-
rowly regulated application, as is the case with fat replacers
which may be used in only a few products, makes intake
easier to assess. In contrast, genetically modified foods
such as soy, despite best efforts, are not really traceable.
Observational studies themselves are subject to bias because
individuals have chosen to use the product in question. The
individual who uses a novel food may have very different
characteristics from one who does not choose to. Confound-
ing lifestyle factors must thus be considered. Another major
challenge in active surveillance is the large population and
long time period required; the cost can be well beyond
what any single company may be willing to bear16. However,
since long term outcomes are of greatest interest, the studies
must also be of sufficient duration, with a large sample size
and must ensure subjects are not differentially lost to follow
up. The best epidemiological model for this type of evalu-
ation is a cluster randomised controlled trial in which the
observation is based on the community and not on the indi-
viduals in isolation. We are presently testing several dietary
and public health interventions using this approach18,19
(Table 1).
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Relationship between Academia and Industry
While academic and industrial partners may find areas of
overlapping interest and competence, the areas of core
competence for each should be established early on. For
example, the industry partner should be solely responsible
for issues related to profit and business development. If
extensive and expensive population studies are needed to
prove efficacy and effectiveness, industry may need to form
broad alliances or partnerships to develop the necessary evi-
dence to comply with progressively complex regulatory
demands. As consumers gain greater influence on food and
nutrition policy, the regulatory framework needs to
balance the industrial interest for profit with the demand by
academic advocates to protect public health interests. This
tension has special relevance in the setting of limits for
health claims or other marketing schemes that in fact may
sometimes conflict with dietary guidelines set as a basis for
consumer education and health promotion. Academia has a
clear role in developing the scientific concepts, defining
the standards for what constitutes evidence, conducting the
necessary research to document efficacy and cost effective-
ness, providing independent information to regulatory
bodies and ultimately to consumers. The academic partner
should keep in mind that sufficiently large sample sizes are
necessary for valid clinical trials of efficacy. Moreover
the ultimate measure of benefit is not only effectiveness
but cost effectiveness that considers if resources are being
well spent in relation to the benefits obtained. These con-
siderations are critical in taking the results from one setting
to another; a product may be effective in populations that
are receiving inadequate diets but may confer no benefit
and maybe even harm populations that are well fed.
The cost of a functional food relative to foods that supply
the protective elements naturally for equal benefits may
not justify their introduction. These types of evaluations
commonly require collaborations between academic groups
in order to run the necessary large multi-centre, multi-sites
studies, considering biological impact as well as economic
costs to consumer16.
Public interest rather than commercial interest must guide
the product development process for academic-industry part-
nerships to be successful. The determination of what is in
the public interest should not be left to the individual judg-
ment of each partner, but should be addressed globally, with
consideration given to the following concerns.
. It should be clearly established that the product should
benefit not only the industrial sector who stands to
profit but also the consumer who will be addressing a
real need.
. Under no circumstances should information be withheld
from the public because it conflicts with industry’s finan-
cial gain or other profit-related motives.
. Weak, unsubstantiated, science should never be used as a
basis for product development or promotion.
. The regulatory process should not be short-circuited in the
interest of getting a product rapidly on the market.
. Patents should be held institutionally (industry or
academic institutions) rather than by individuals in order
to preserve impartiality by academic or industry research-
ers in judging the evidence from research studies20,21,22.
It should be noted that academic researchers who retain
greater independence from their industrial partners achieve
higher academic standing. A survey-based study demon-
strated that the most effective and productive researchers in
the USA get less than half of their funding from industry23.
When academic researchers in the USA receive more than
two thirds of total funding from industry they tend to be
less productive and their articles have less influence in
their respective fields. Over the past decade, norms for
public disclosures of competing interests, real conflict of
interests and potential for perceived conflict of interests
have been progressively implemented by scientific journals,
universities, national governments and international agencies.
These norms apply to the dissemination of scientific infor-
mation, the work of technical experts, scientific panels that
review evidence or establish recommendations with public
or social implications24,21,22,25.
What can be done in practice to facilitate successful
academic-industry partnerships?
One objective of AIPs is to define the ways to optimise the
development and launch of new, beneficial products and to
identify factors which hinder the process. The role of
Table 1. Characteristic of Controlled Evaluation Study
Study Aspect
Hypothesis † All studies must be hypothesis-driven, with the hypothesis as the basis for
a potential claim
Study Design † Blinded, randomised, parallel group or crossover, appropriate exclusion criteria,
study approved by ethics committees
Patient Population † Product must be effective in the general population or a large, at-risk population,
subjects should be randomly assigned and with sufficient number to secure good
match between groups
Sample size † Sufficient number of subjects to secure not only significance of outcomes related to
efficacy but also identify changes in prevalence of adverse effects.
Outcome † Target function needs to be beyond adequate nutrition, impacting health and
well-being or reduction of risk for disease
Efficacy Evaluation † Relies on biomarkers correlating to an endpoint or intermediate markers
representing an endpoint relevant to health
modified from(16).
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research in innovation, and the roles of industry, academics,
expert committees, regulatory bodies, and physicians and
consumers in the process leading from innovation to
implementation must be examined in order to identify fac-
tors that facilitate or impede the process. The key to suc-
cessful development of new foods and ingredients is to
remain focused on the interest of the consumer, because
functional foods that are not consumed can serve no health-
ful purpose, and no profits can be made. Industry serves
many functions in the development of food products, includ-
ing the generation of ideas and knowledge on consumer
needs, and the provision of funding and/or facilities to con-
duct the research.
Much of the tension between marketing professionals
(MP) and scientists arises from the conflicting desire of
the scientist to methodically determine how a novel food
product can best be used, and the desire of the MP to
quickly and profitably bring new products to the widest
market possible. One resolution is for both scientists and
marketing groups to remain focused on the needs of the
consumer as the target for both research and sales. One of
the challenges in getting consumers to accept novel func-
tional foods and ingredients is that the novelty that is
appealing may also breed suspicion. In other words, the
goal must be to come up with products that fulfill a consu-
mer need but that does not cause excessive fear such that
the product is deemed too novel to be trusted. Consumer
education is essential in creating a level of trust; building
brand confidence allows the consumer to identify with the
product and feel comfortable using it. Industry must play
a large role in accurately relaying scientific information to
the consumer, so that the popular media is not the consu-
mer’s only source of information.
Controlled studies to assess the health benefits of specific
foods should be based on a hypothesis that can be rigorously
tested using randomised, long term trials with predetermined
efficacy and effectiveness outcomes. Ideally, this would
involve use of cluster randomised designs providing data
from different settings, collected in a standardised way so
that pooled data from multiple sites can be used to assess
effectiveness and safety.
Good research is the only sound basis for a successful
functional food product; having an effective way to commu-
nicate information concerning beneficial functional foods to
consumers and making sure the foods produced are targeted
to a discerning consumer base is equally critical. Since
industry ultimately brings products to market, it is important
to determine what industry can do to develop functional
foods that both benefit the public interest and are profitable.
We do need strong science to back up claims. Regulators
certainly have a role in terms of defining how much science
is sufficient to allow for health claims. Regulatory bodies
need to protect the consumer without discouraging inno-
vation. Regulatory legislation to meet these goals is part
of the process, but less restrictive ways to promote inno-
vation are also needed. A more useful approach is to have
a transparent regulatory process where regulatory bodies,
industry, academia and the public interact in the develop-
ment of guidance for the introduction of new food products,
and where product development is an iterative process
where products can be re-evaluated and refined even
after they are marketed. The establishment of national
food standards agencies in most European countries and in
the EU region demonstrates that this in fact is feasible
and of benefit to both industry and the public alike.
Finally we must also acknowledge that in the real world
there are conflicting interests between scientists, marketing
and business interests, and the public. It may appear to
some that the conflict of interest issue is often over-empha-
sised in public discussions, and discussions among academic
colleagues, however recent experience demonstrates that
unless these issues are addressed openly the whole foun-
dation of public trust suffers25–27. How investigators that
participate in industry partnerships address the following
issues, serves to illustrate the nature of the potential
problems:
1. Work with their institutions to ensure requirements are
fulfilled and relationships are fairly and effectively
reviewed and overseen?
2. Address problems related to access, analysis, and disse-
mination of research information, data, and materials in
industry relationships?
3. Operate with transparency and accountability in industry
consulting relationships (consulting, advisory board
membership, funding for travel to meetings and confer-
ences)?
4. Address conflict of interest issues in their entrepreneurial
activities (involvement in start-up companies, patents and
technology licensing)?
5. Minimise the negative impacts of those relationships on
training and educational activities?
6. Protect human research participants against risks to their
health or personal integrity?
These problems are real and must be addressed proactively
and openly by academia and industry alike as suggested
by the recent FASEB recommendations summarised in
(see box 1)28. We also need to interpret what is in the
public interest by having a forum for open discussion
which includes the public. The public and the consumer
must be invited to enter the debate. This is already being
done in many countries by consumer interest groups, aca-
demic advocates and the government. National and inter-
national regulatory agencies should also be involved. Infant
formula is a good example of how public interest in the
1960’s brought about the code of infant formula marketing,
which continues to monitor the commercial practices and
marketing conduct of industry. We must keep the relationship
between industry and academia transparent and open for
review, because in the final analysis nobody but the public
can defend its own interests.
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BOX 1. FASEB guiding principles to aid investigators in addressing critical issues in interactions with industry. (modified from FASEB 200628)
1. Investigators have a responsibility and commitment to conduct scientific activities objectively and with the highest professional standards.
2. The primary responsibility of full-time investigators is to the institution. Outside activities shall complement, not compromise, institutional
responsibilities.
3. It is appropriate and beneficial for academic institutions to develop and enforce their own mechanisms of review and oversight of investigator
relationships with industry.
4. The academic community can and shall monitor itself through peer review of industry relationships. Institutional committees that include peer
members from the same institution are appropriate and effective in reviewing disclosures of investigators’ industry relationships.
5. Investigators want and need clear guidance, efficient processes, and adequate support mechanisms from their institution throughout their
participation in industry relationships.
6. Investigators shall have access to, and be involved in the analysis and/or interpretation of all data generated in the research.
7. Mutual understanding of constraints, principles, and policies regarding access, analysis, and dissemination of research information, data, and
materials among investigators and their students and trainees, institutions, and sponsors is beneficial.
8. Investigators shall not enter into agreements with companies that prevent publication of research results. Pre-publication review by an
industry sponsor shall occur in a timely manner (no more than thirty to sixty days) so as not to unnecessarily delay study publication.
9. Investigators shall be aware of and adhere to individual journal policies on disclosure of industry relationships.
10. Consulting and advisory board relationships shall be carried out in a transparent and accountable manner and be disclosed as they are
initiated.
11. When investigators have consulting relationships with an investment firm related to their area of expertise, all parties shall be aware of the
specific circumstances involved.
12. Investigators shall not use public funds to the benefit of a company, unless this is the explicit purpose of the mechanism used to fund the
research (e.g., Small Business Innovation Research and similar grants).
13. When investigators own significant equity in a company with which research is conducted, all parties shall be aware of the special
circumstances involved.
14. When holding a significant role in a start-up company, investigators shall be guided by agreed-upon limits to the scope of the relationship.
15. Investigators shall be aware of and adhere to requirements of public funding sources related to disclosure of inventions. Investigators shall
adhere to patent law and institutional requirements.
16. Investigators shall not seek to influence their institution’s technology transfer decisions for personal gain.
17. A mentor’s outside commercial interests shall avoid impeding a trainee’s timely progress toward his/her degree, restricting a trainee’s right to
publish his/her dissertation research in a timely manner, compromising a trainee’s career progress, or restricting a trainee’s freedom of
inquiry.
18. Mentors and institutions should make trainees aware of their rights and responsibilities in industry relationships.
19. Investigators shall regard all significant financial interests in research involving human subjects as potentially problematic and thus requiring
close scrutiny.
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